How many insider trades does FilingIQ track for BHVN?

FilingIQ tracks 720 Form 4 insider transactions for BHVN (Biohaven Ltd.), covering filings from Aug 4, 2017 onwards. 14 of those were filed in the last 90 days.

Are BHVN insiders net buyers or net sellers?

Across the full Form 4 history for BHVN, 71 transactions (10%) were open-market purchases and 288 (40%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does BHVN insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is BHVN in?

Biohaven Ltd. (BHVN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.42B.

BHVN insider trading

NYSE Healthcare

Biohaven Ltd. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

720

Last 90 days

Buys / sells

10% / 40%

Market cap

$1.42B

About Biohaven Ltd.

Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 that is in Phase 2 clinical trial for the treatment of migraines and pain disorders; BHV-1510, which is in Phase ½ trial that targets advanced or metastatic epithelial tumors; and BHV-8000, a product candidate that completed Phase 1 clinical trial for the treatment of Alzheimer's and Parkinson's disease, and multiple sclerosis, as well as prevention of amyloid-related imaging abnormalities. It is also developing BHV-1300, which in Phase 1 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 1 trial for IgA nephropathy; BHV-1100, which is in Phase 1 trial for multiple myeloma patients; BHV-1600, which is in Phase 1 trial for the treatment of peripartum cardiomyopathy; BHV-1310 that is in preclinical trial for the treatment of generalized myasthenia gravis and other acute exacerbations or flares; BHV-1530, which is in preclinical trial to treat urothelial cancer; BHV-1500 that is in preclinical trial for Hodgkin's lymphoma; and BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors. The company has strategic partnerships with Merus N.V., GeneQuantum Healthcare (Suzhou) Co. Ltd., Aimed Bio, Inc., Yale University, Katholieke Universiteit Leuven, Bristol Meyers Squibb, and Hangzhou Highlightll Pharmaceutical Co. Ltd. Biohaven Ltd. was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Company website: www.biohaven.com

BHVN insider activity at a glance

FilingIQ has scored 720 insider transactions for BHVN since Aug 4, 2017. The most recent filing in our index is dated Apr 28, 2026.

Across the full history, 71 open-market purchases and 288 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on BHVN insider trades is 55.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live BHVN trades on FilingIQ Raw filings on SEC EDGAR

Latest BHVN Form 4 filings

Coric Vlad Chief Executive Officer

P Oct 5, 2023

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Top insiders trading BHVN

Coric Vlad

23 trades · score 70.8

13F funds holding BHVN

Ikarian Capital, LLC

$12.23M · 1.3% of AUM

STEMPOINT CAPITAL LP

$8.10M · 2.4% of AUM

Frequently asked

How many insider trades does FilingIQ track for BHVN?: FilingIQ tracks 720 Form 4 insider transactions for BHVN (Biohaven Ltd.), covering filings from Aug 4, 2017 onwards. 14 of those were filed in the last 90 days.
Are BHVN insiders net buyers or net sellers?: Across the full Form 4 history for BHVN, 71 transactions (10%) were open-market purchases and 288 (40%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does BHVN insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is BHVN in?: Biohaven Ltd. (BHVN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.42B.

Methodology & sources

Every BHVN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.